Stockhead’s Sarah Hughan sits down with Aroa Biosurgery’s (ASX:ARX) founder and CEO Brian Ward to get the short end of the long story on the company’s latest news.

The company’s biomaterial ECM technology aims to improve the rate and quality of soft tissue repair.

It also has several other products supported by peer-reviewed publications, and sales productivity around the world is building momentum.

Tune in to hear Aroa Biosurgery’s Brian Ward on why the company’s mission is needed, upcoming milestones, and more.

 

This video was developed in collaboration with Aroa Biosurgery, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.

Read MoreHealthMedtech

Featured Companies

You might be interested in